Publication

Date Item Type Full Text Status

10 January 2025

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders : A pharmacovigilance perspective. (2025) S Chiappini, A Guirguis, N Schifano, J Corkery, F Semeraro, A Mosca, G D'Andrea, G D Papanti, D Arillotta, G Floresta, G Martinotti and F Schifano

19 October 2020

High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. (2020) Norbert Scherbaum, Friedrich Seiffert, Fabrizio Schifano, Michael Specka, Udo Bonnet and Stefan Bender

4 January 2016

The potential utility of some legal highs in CNS disorders. (2016) Colin Davidson and Fabrizio Schifano picture_as_pdf

December 2012

The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) : A brief review. (2012) John Corkery, E. Durkin, S. Elliott, Fabrizio Schifano and A. Hamid Ghodse

2012

2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) : A preliminary review. (2012) John Corkery, Fabrizio Schifano, A. Hamid Ghodse, S. Elliott and Ornella Corazza

Identifying emerging trends in recreational drug use : outcomes from the Psychonaut Web Mapping Project. (2012) Paolo Deluca, Zoe Davey, Ornella Corazza, Manuela Pasinetti, C. Pezzolesi, Fabrizio Schifano, Lucia Di Furia, Magi Farre, Marta Torrens, Liv Flesland, Arvid Skutle, E. Iversen, Miia Mannonen, A. Majava, Teuvo Peltoniemi, Norbert Scherbaum, Holger Siemann and Peer van der Kreeft picture_as_pdf

2011

Suicide verdicts as opposed to accidental deaths in substance-related fatalities (UK, 2001–2007). (2011) A.E. Vento, M. Pompili, Fabrizio Schifano, John Corkery, M. Innamorati, P. Girardi and H. Ghodse picture_as_pdf

2006

Are placebo-controlled trials still important for obsessive compulsive disorder? (2006) Naomi Fineberg, C. Hawley and T.M. Gale